Literature DB >> 53948

Bleomycin in testicular teratomas.

K W Brunner, R W Sonntag.   

Abstract

Bleomycin and its combinations have a definite place in the treatment of metastatic testicular carcinomas other than seminomas and may also prove to be effective, when given as adjuvant postoperative therapy in state II disease. A study, using the combination of Bleomycin and CCNU in 17 patients with metastatic testicular teratoma, is reported. A remission rate of 59% has been observed. Only patients with a complete remission had a satisfactory remission duration. Sequential combinations, using all drugs effective in this disease, may be the most promising way to further improve therapeutic results in terms of remission rate and survival.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 53948     DOI: 10.1007/bf00312250

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  5 in total

1.  [Bleomycin for malignant tumours of the genitals of the male (author's transl)].

Authors:  P Rathert; B Terhorst; W Lutzeyer
Journal:  Urologe A       Date:  1974-03       Impact factor: 0.639

2.  Vinblastine (NSC-49842) and bleomycin (NSC-125066) therapy for disseminated testicular tumors.

Authors:  S C Spigel; C A Coltman
Journal:  Cancer Chemother Rep       Date:  1974 Mar-Apr

3.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

4.  Clinical study with bleomycin.

Authors:  S Shastri; R E Slayton; J Wolter; C P Perlia; S G Taylor
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

5.  Treatment of metastatic testicular carcinoma with bleomycin (NSC-125066) used alone or in combination with CCNU (NSC-79037).

Authors:  R W Sonntag; K W Brunner; K Batz; H J Ryssel
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.